샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784889

세계의 말단비대증 치료 시장

Acromegaly Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 297 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 말단비대증 치료 시장은 2030년까지 17억 달러에 도달

2024년에 13억 달러로 추정되는 말단비대증 치료 세계 시장은 2024-2030년의 분석 기간에 CAGR 3.9%로 성장하여 2030년에는 17억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 소마토스타틴 유사체는 CAGR 3.2%를 나타내고, 분석 기간 종료시에는 6억 950만 달러에 이를 것으로 예측됩니다. GHRA 부문의 성장률은 분석 기간중 CAGR 3.9%로 추정됩니다.

미국 시장은 3억 6,750만 달러로 추정, 중국은 CAGR 7.0%로 성장 예측

미국의 말단비대증 치료 시장은 2024년에 3억 6,750만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억 4,010만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.6%와 3.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%를 보일 전망입니다.

세계의 말단비대증 치료 시장 - 주요 동향과 촉진요인 정리

말단비대증이란 무엇이며, 왜 효과적인 치료가 필수적인가?

말단비대증은 드물지만 성장호르몬(GH)의 과잉 생산으로 인해 발생하는 심각한 호르몬 장애로, 일반적으로 양성 뇌하수체 종양에 의해 발생합니다. 치료하지 않고 방치하면 심혈관 질환, 당뇨병, 관절염, 장기 비대 등의 심각한 합병증을 유발할 수 있습니다. 조기 및 효과적인 치료의 필요성으로 인해 첨단 거대세포증 치료 시장은 내분비학의 초점이 되고 있습니다. 주요 치료 방법으로는 뇌하수체 종양의 외과적 절제, 소마토스타틴 유사체(SSA), 도파민 작용제, GH 수용체 길항제 등의 내과적 치료, 수술이나 약물 치료가 불충분한 경우 방사선 치료 등이 있습니다. 진단의 발전과 질병에 대한 이해도가 높아짐에 따라 말단비대증은 더 일찍 발견되고 있으며, GH 수치를 조절할 뿐만 아니라 증상을 완화하고 환자의 삶의 질을 개선할 수 있는 효과적인 치료에 대한 수요가 증가하고 있습니다.

기술 및 약리학의 발전은 첨단 거대세포증 치료를 어떻게 변화시키고 있는가?

첨단 거대세포증 치료를 둘러싼 환경은 특히 약리학적 및 수술적 접근법에서 눈부신 기술 혁신을 목격했습니다. 옥트레오타이드, 란레오타이드와 같은 장기지속형 소마토스타틴 유사체의 개발로 주사 횟수가 줄어들어 환자들의 순응도가 크게 개선되었습니다. GH 수용체 길항제인 페그비소망과 같은 새로운 치료법은 IGF-1 수치를 정상화하고 SSA에 내성이 있는 환자의 증상을 관리하는 데 매우 우수한 효과를 보이고 있습니다. 또한, 유전자 및 분자 프로파일링을 통해 임상의가 환자 개개인의 필요에 따라 맞춤형 치료를 할 수 있게 됨에 따라 개인 맞춤형 의료도 인기를 끌고 있습니다. 수술 영역에서는 첨단 영상진단과 신경 내비게이션 시스템을 기반으로 한 경추경 수술과 같은 저침습적 기술이 회복 시간과 위험을 최소화하면서 수술 결과를 개선하고 있습니다. 또한, 원격 의료와 원격 모니터링 도구의 출현으로 호르몬 수치와 치료 효과를 지속적으로 모니터링할 수 있게 되어 환자 관리에 혁명을 일으켰습니다. 이러한 발전은 종합적으로 말단비대증 환자의 표준 치료를 개선하고, 좋은 결과를 가져오고, 치료 시장의 성장을 가속하고 있습니다.

시장을 형성하고 있는 지역과 환자층은?

말단비대증의 유병률은 전 세계적으로 편차가 있으며, 진단율과 치료 접근성의 지역적 차이가 시장에 큰 영향을 미치고 있습니다. 현재 북미와 유럽이 첨단 거대세포증 치료 시장을 독점하고 있는데, 이는 탄탄한 의료 인프라, 높은 인지도, 첨단 진단 및 치료 도구에 대한 접근성 확산에 기인합니다. 또한, 이 지역들은 대형 제약회사들의 존재와 치료 효과를 향상시키기 위한 광범위한 연구개발 활동의 혜택을 누리고 있습니다. 반면, 아시아태평양, 라틴아메리카, 중동의 신흥 시장은 의료비 지출 증가, 질병에 대한 인식 증가, 전문 의료에 대한 접근성 향상으로 인해 빠른 성장세를 보이고 있습니다. 환자 인구 통계에 따르면, 말단비대증은 주로 30-50세 성인에게 발병하지만, 증상이 서서히 나타나기 때문에 진단이 늦어지는 경우가 많습니다. 인식 개선 캠페인과 검진 프로그램을 통해 조기 발견을 강화하는 노력은 환자층을 재조합하고 각 지역별로 표적 치료에 대한 수요를 증가시키고 있습니다.

말단비대증 치료제 시장의 성장을 가속하는 요인은 무엇인가?

말단비대증 치료시장이러한 성장은 약리학 치료의 발전, 질병에 대한 인식 증가, 고급 진단 도구의 가용성 확대 등 여러 가지 요인에 의해 주도되고 있습니다. 지속형 소마토스타틴 유사체, GH 수용체 길항제 등 새로운 약물의 개발로 말단비대증 환자, 특히 기존 치료에 저항성을 보이는 환자들의 치료 성적이 크게 개선되었습니다. 의료 기관과 환자 지원 단체의 인식 개선 캠페인은 이 질환의 조기 진단과 효과적인 관리를 촉진하는 데 중요한 역할을 하고 있습니다. 최소침습 수술 기법의 도입과 영상 기술의 향상으로 치료의 정확도가 더욱 향상되어 합병증과 회복에 소요되는 시간이 단축되고 있습니다. 또한, 신흥 시장에서의 헬스케어 인프라에 대한 투자 증가는 전문 내분비학 치료에 대한 접근성을 확대하며 시장 성장을 견인하고 있습니다. 첨단 거대질환 관리에 원격의료와 디지털 헬스 솔루션이 통합되면서 원격 진료와 모니터링이 용이해지고, 전 세계 환자의 진료 연속성이 확보된 것도 시장 확대에 기여하고 있습니다.

부문

약제 유형(소마토스타틴 유사체, GHRA, 기타 약제 유형), 최종사용자(병원 및 진료소 최종사용자, 기타 최종사용자)

조사 대상 기업 예

  • Chiesi USA, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Ipsen Biopharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Ltd.
  • Novartis AG
  • Peptron
  • Pfizer, Inc.
  • Recordati Rare Diseases, Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM에 쿼리-하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.12

Global Acromegaly Treatment Market to Reach US$1.7 Billion by 2030

The global market for Acromegaly Treatment estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$609.5 Million by the end of the analysis period. Growth in the GHRA segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$367.5 Million While China is Forecast to Grow at 7.0% CAGR

The Acromegaly Treatment market in the U.S. is estimated at US$367.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$340.1 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Acromegaly Treatment Market - Key Trends & Drivers Summarized

What Is Acromegaly, and Why Is Effective Treatment Essential?

Acromegaly is a rare but serious hormonal disorder caused by excessive production of growth hormone (GH), typically due to a benign pituitary gland tumor. If left untreated, the condition can lead to severe complications, including cardiovascular disease, diabetes, arthritis, and organ enlargement. The necessity for early and effective treatment has made the acromegaly treatment market a focal point in endocrinology. The primary treatment options include surgical removal of the pituitary tumor, medical therapies like somatostatin analogs (SSAs), dopamine agonists, and GH receptor antagonists, as well as radiation therapy for cases where surgery or medications are insufficient. With advancements in diagnostics and an increased understanding of the disease, acromegaly is now being identified at earlier stages, leading to a growing demand for effective treatments that not only control GH levels but also alleviate symptoms and improve patient quality of life.

How Are Technological and Pharmacological Advancements Transforming Acromegaly Treatment?

The acromegaly treatment landscape has witnessed remarkable innovations, particularly in pharmacological and surgical approaches. The development of long-acting somatostatin analogs, such as octreotide and lanreotide, has significantly improved patient compliance by reducing the frequency of injections required. Emerging therapies, such as pegvisomant, a GH receptor antagonist, have shown exceptional efficacy in normalizing IGF-1 levels and managing symptoms in patients resistant to SSAs. Personalized medicine is also gaining traction, with genetic and molecular profiling enabling clinicians to tailor treatments based on individual patient needs. In the surgical domain, minimally invasive techniques such as transsphenoidal surgery, supported by advanced imaging and neuronavigation systems, have enhanced surgical outcomes while minimizing recovery time and risks. Additionally, the advent of telemedicine and remote monitoring tools has revolutionized patient management, enabling continuous monitoring of hormone levels and treatment efficacy. These advancements have collectively elevated the standard of care for acromegaly patients, driving positive outcomes and fostering growth in the treatment market.

Which Regions and Patient Demographics Are Shaping the Market?

The prevalence of acromegaly varies globally, with regional differences in diagnosis rates and treatment accessibility significantly influencing the market. North America and Europe currently dominate the acromegaly treatment market, driven by robust healthcare infrastructure, high awareness levels, and widespread access to advanced diagnostic and therapeutic tools. These regions also benefit from the presence of major pharmaceutical companies and extensive research and development activities aimed at improving treatment efficacy. In contrast, emerging markets in Asia-Pacific, Latin America, and the Middle East are witnessing rapid growth due to increasing healthcare expenditures, rising disease awareness, and improving access to specialized care. Patient demographics reveal that acromegaly primarily affects adults aged 30 to 50, although delayed diagnosis is common due to the gradual onset of symptoms. Efforts to enhance early detection through awareness campaigns and screening programs are reshaping the patient pool, driving greater demand for targeted treatments across regions.

What Factors Are Driving Growth in the Acromegaly Treatment Market?

The growth in the Acromegaly Treatment market is driven by several factors, including advancements in pharmacological therapies, increasing awareness of the condition, and the growing availability of advanced diagnostic tools. The development of novel drugs, such as long-acting somatostatin analogs and GH receptor antagonists, has significantly improved treatment outcomes for patients with acromegaly, particularly those resistant to conventional therapies. Rising awareness campaigns by healthcare organizations and patient advocacy groups have played a crucial role in promoting early diagnosis and effective management of the disease. The adoption of minimally invasive surgical techniques and improved imaging technologies has further enhanced treatment precision, reducing complications and recovery times. Additionally, increasing investments in healthcare infrastructure in emerging markets have expanded access to specialized endocrinology care, driving market growth in these regions. The integration of telemedicine and digital health solutions into acromegaly management has also contributed to market expansion by facilitating remote consultations and monitoring, ensuring continuity of care for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Acromegaly Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Somatostatin Analogs, GHRA, Other Drug Types); End-Use (Hospitals & Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 63 Featured) -

  • Chiesi USA, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Ipsen Biopharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Ltd.
  • Novartis AG
  • Peptron
  • Pfizer, Inc.
  • Recordati Rare Diseases, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Acromegaly Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis of Pituitary Disorders Drives Demand for Acromegaly Treatment
    • Expansion of Endocrinology and Rare Disease Specialties Throws the Spotlight on Timely Acromegaly Management
    • Increased Adoption of Somatostatin Analogs Strengthens First-Line Therapeutic Use in Hormonal Regulation
    • Technological Advancements in MRI and IGF-1 Testing Enhance Detection and Monitoring Capabilities
    • Regulatory Approvals for Long-Acting Injectables and Depot Formulations Spur Patient Adherence
    • Growth in Use of GH Receptor Antagonists Propels Market for Second-Line and Resistant Case Therapies
    • Improved Reimbursement and Access to Biologics Encourages Widespread Treatment Initiation
    • Development of Combination Drug Therapies Expands Personalized Treatment Pathways
    • Emergence of Oral Somatostatin Formulations Enhances Convenience and Quality of Life for Patients
    • Integration of Endocrinology and Neurosurgery Supports Multidisciplinary Care Models
    • Increasing Global Research in Pituitary Tumor Genetics Strengthens Precision Medicine Applications
    • Rising Number of Surgical Interventions Promotes Long-Term Post-Operative Pharmacologic Management
    • Expansion of Rare Disease Advocacy Networks Drives Diagnosis and Access in Underserved Populations
    • Availability of Disease-Specific Patient Registries Supports Real-World Evidence and Market Development
    • Strategic Collaborations Between Pharma and Academic Institutions Accelerate Therapeutic Innovation
    • Adoption of Digital Health Tools and Remote Monitoring Enhances Patient Follow-Up and Treatment Adjustment
    • Emerging Biosimilars and Competitive Biologics Landscape Improves Market Accessibility
    • Public Health Initiatives Focused on Endocrine Disorders Create Awareness in Primary Care Settings
    • Focus on Long-Term Disease Burden Reduction Sustains Investment in Safe and Effective Therapeutic Pipelines
    • Global Expansion of Reference Centers for Hormonal Disorders Strengthens Clinical Capacity and Treatment Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acromegaly Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acromegaly Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for GHRA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for GHRA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for GHRA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Acromegaly Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Acromegaly Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Acromegaly Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Acromegaly Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제